

PHARMACY POLICY STATEMENT

DATE	ACTION/DESCRIPTION
05/28/2021	New policy for Empaveli created.
07/27/2023	Added new references. Added requirement that the member must be symptomatic. Moved Soliris note to dosing section. Shortened vaccine requirement statement.
10/13/2023	Added injector to dosing.

References:

1. Empaveli [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; 2023.
2. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. *N Engl J Med.* 2021;384(11):1028-1037. doi:10.1056/NEJMoa2029073
3. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Hematology Am Soc Hematol Educ Program.* 2016;2016(1):208-216. doi:10.1182/asheducation-2016.1.208
4. Patriquin CJ, Kiss T, Caplan S, et al. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. *Eur J Haematol.* 2019;102(1):36-52. doi:10.1111/ejh.13176
5. Devos T, Meers S, Boeckx N, et al. Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. *Eur J Haematol.* 2018;101(6):737-749. doi:10.1111/ejh.13166
6. Bodó I, Amine I, Boban A, et al. Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations. *Adv Ther.* 2023;40(6):2752-2772. doi:10.1007/s12325-023-02510-4
7. Bhak RH, Mody-Patel N, Baver SB, et al. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. *Curr Med Res Opin.* 2021;37(11):1913-1923. doi:10.1080/03007995.2021.1971182

Effective date: 04/01/2024

Revised date: 10/13/2023